PMID- 37794661
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231031
IS  - 1738-3684 (Print)
IS  - 1976-3026 (Electronic)
IS  - 1738-3684 (Linking)
VI  - 20
IP  - 9
DP  - 2023 Sep
TI  - The Use of Phentermine for Obesity in Psychiatric Patients With Antipsychotics.
PG  - 799-807
LID - 10.30773/pi.2023.0045 [doi]
AB  - OBJECTIVE: Phentermine is a commonly used weight-loss agent in the United States, 
      but there is a little information about the use of phentermine for patients with 
      obesity taking antipsychotic medications. METHODS: We gathered 57 patients with 
      obesity taking antipsychotic medications whose phentermine treatment was 
      simultaneous with or after any type of antipsychotic exposure and collected data 
      of clinical information, initial/follow-up anthropometric variables, and adverse 
      events (AEs) for the 6-month study period. RESULTS: In total, the mean body 
      weight reduction (BWR) was 4.45 (7.04) kg, and the mean BWR percent (BWR%) was 
      3.92% (6.96%) at 6 months. Based on the response to phentermine, the patients 
      were classified into two groups: the responder (n=25; BWR% >/=5%) and nonresponder 
      (n=32; BWR% <5%) groups. The responder group's mean BWR and BWR% were 10.13 
      (4.43) kg and 9.35% (4.09%), respectively, at 6 months. The responders had higher 
      rates of anticonvulsant combination therapy (ACT; responder, 72.0% vs. 
      non-responder, 43.8%; p=0.033) and a shorter total antipsychotic exposure 
      duration (responder, 23.9 [16.9] months vs. non-responder, 37.2 [27.6] months; p= 
      0.039). After adjusting age, sex, and initial body weight, ACT maintained a 
      significant association with phentermine response (odds ratio=3.840; 95% 
      confidence interval: 1.082-13.630; p=0.037). In the final cohort, there was no 
      report of adverse or new-onset psychotic symptoms, and the common AEs were sleep 
      disturbances, dry mouth, and dizziness. CONCLUSION: Overall, phentermine was 
      effective and tolerable for patients with obesity taking antipsychotic 
      medications, and ACT (predominantly topiramate) augmented the weight-loss effect 
      of phentermine.
FAU - Kim, Eunju
AU  - Kim E
AD  - Section of Endocrinology, Diabetes and Weight Management, Boston University, 
      Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
AD  - Mood Disorder Clinic and Affective Neuroscience Laboratory, Department of 
      Psychiatry, Seoul National University Bunding Hospital, Seongnam, Republic of 
      Korea.
FAU - Rim, Daniel
AU  - Rim D
AD  - Section of Endocrinology, Diabetes and Weight Management, Boston University, 
      Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
FAU - Shin, Jeong-Hun
AU  - Shin JH
AD  - Section of Endocrinology, Diabetes and Weight Management, Boston University, 
      Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
AD  - Department of Internal Medicine, Hanyang University College of Medicine, Seoul, 
      Republic of Korea.
FAU - Wong, Denise
AU  - Wong D
AD  - Section of Endocrinology, Diabetes and Weight Management, Boston University, 
      Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
FAU - Kim, Dong Wook
AU  - Kim DW
AD  - Section of Endocrinology, Diabetes and Weight Management, Boston University, 
      Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
LA  - eng
PT  - Journal Article
DEP - 20230919
PL  - Korea (South)
TA  - Psychiatry Investig
JT  - Psychiatry investigation
JID - 101242994
PMC - PMC10555508
OTO - NOTNLM
OT  - Antipsychotics
OT  - Obesity
OT  - Phentermine
OT  - Safety
OT  - Topiramate
COIS- Conflicts of Interest The authors have no potential conflicts of interest to 
      disclose.
EDAT- 2023/10/05 06:43
MHDA- 2023/10/05 06:44
PMCR- 2023/09/01
CRDT- 2023/10/05 01:35
PHST- 2023/02/10 00:00 [received]
PHST- 2023/06/14 00:00 [accepted]
PHST- 2023/10/05 06:44 [medline]
PHST- 2023/10/05 06:43 [pubmed]
PHST- 2023/10/05 01:35 [entrez]
PHST- 2023/09/01 00:00 [pmc-release]
AID - pi.2023.0045 [pii]
AID - pi-2023-0045 [pii]
AID - 10.30773/pi.2023.0045 [doi]
PST - ppublish
SO  - Psychiatry Investig. 2023 Sep;20(9):799-807. doi: 10.30773/pi.2023.0045. Epub 
      2023 Sep 19.